Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes

The sodium‐glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduces heart failure in diabetes, but underlying mechanisms remain elusive. We hypothesized that empagliflozin could counteract the senescence of cardiac stromal cells (CSC), the action of which limits cardiac damage and cardiac fib...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Cell Mol Med
Main Authors: Madonna, Rosalinda, Doria, Vanessa, Minnucci, Ilaria, Pucci, Angela, Pierdomenico, Donato Sante, De Caterina, Raffaele
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687009/
https://ncbi.nlm.nih.gov/pubmed/32940423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15699
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares